Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

BcCluster: A Bladder Cancer Database at the Molecular Level.

Bhat A, Mokou M, Zoidakis J, Jankowski V, Vlahou A, Mischak H.

Bl Cancer. 2016 Jan 7;2(1):65-76.

2.

Biomarkers of alcohol misuse: recent advances and future prospects.

Jastrzębska I, Zwolak A, Szczyrek M, Wawryniuk A, Skrzydło-Radomańska B, Daniluk J.

Prz Gastroenterol. 2016;11(2):78-89. doi: 10.5114/pg.2016.60252. Epub 2016 Jun 8. Review.

3.

Hydroxylated collagen peptide in urine as biomarker for detecting colorectal liver metastases.

Lalmahomed ZS, Bröker ME, van Huizen NA, Coebergh van den Braak RR, Dekker LJ, Rizopoulos D, Verhoef C, Steyerberg EW, Luider TM, IJzermans JN.

Am J Cancer Res. 2016 Jan 15;6(2):321-30. eCollection 2016.

4.

The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.

Knoppova B, Reily C, Maillard N, Rizk DV, Moldoveanu Z, Mestecky J, Raska M, Renfrow MB, Julian BA, Novak J.

Front Immunol. 2016 Apr 12;7:117. doi: 10.3389/fimmu.2016.00117. eCollection 2016. Review.

5.

Type 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profile.

Liu CW, Atkinson MA, Zhang Q.

Proteomics. 2016 May;16(9):1432-46. doi: 10.1002/pmic.201500333. Epub 2016 Apr 13.

PMID:
26935967
6.

Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids.

Wu C, Duan J, Liu T, Smith RD, Qian WJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 15;1021:57-68. doi: 10.1016/j.jchromb.2016.01.015. Epub 2016 Jan 12.

7.

Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis.

Eloot S, Schneditz D, Cornelis T, Van Biesen W, Glorieux G, Dhondt A, Kooman J, Vanholder R.

PLoS One. 2016 Jan 22;11(1):e0147159. doi: 10.1371/journal.pone.0147159. eCollection 2016.

8.

Comprehensive maternal serum proteomics identifies the cytoskeletal proteins as non-invasive biomarkers in prenatal diagnosis of congenital heart defects.

Chen L, Gu H, Li J, Yang ZY, Sun X, Zhang L, Shan L, Wu L, Wei X, Zhao Y, Ma W, Zhang H, Cao S, Huang T, Miao J, Yuan Z.

Sci Rep. 2016 Jan 11;6:19248. doi: 10.1038/srep19248.

9.

Biomarker discovery in mass spectrometry-based urinary proteomics.

Thomas S, Hao L, Ricke WA, Li L.

Proteomics Clin Appl. 2016 Apr;10(4):358-70. doi: 10.1002/prca.201500102. Epub 2016 Feb 11. Review.

PMID:
26703953
10.

New Insights into the Pathogenesis of IgA Nephropathy.

Novak J, Rizk D, Takahashi K, Zhang X, Bian Q, Ueda H, Ueda Y, Reily C, Lai LY, Hao C, Novak L, Huang ZQ, Renfrow MB, Suzuki H, Julian BA.

Kidney Dis (Basel). 2015 May;1(1):8-18. Epub 2015 May 1.

11.

Defining cancer-related fatigue for biomarker discovery.

Filler K, Saligan LN.

Support Care Cancer. 2016 Jan;24(1):5-7. doi: 10.1007/s00520-015-2965-5. Epub 2015 Oct 5. No abstract available.

PMID:
26438143
12.

Quantitative mass spectrometry of urinary biomarkers.

Jerebtsova M, Nekhai S.

J Integr OMICS. 2014 Dec 1;4(2):69-78.

13.

OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.

Kraus VB, Blanco FJ, Englund M, Henrotin Y, Lohmander LS, Losina E, Önnerfjord P, Persiani S.

Osteoarthritis Cartilage. 2015 May;23(5):686-97. doi: 10.1016/j.joca.2015.03.002. Review.

14.

Protein interactome of muscle invasive bladder cancer.

Bhat A, Heinzel A, Mayer B, Perco P, Mühlberger I, Husi H, Merseburger AS, Zoidakis J, Vlahou A, Schanstra JP, Mischak H, Jankowski V.

PLoS One. 2015 Jan 8;10(1):e0116404. doi: 10.1371/journal.pone.0116404. eCollection 2015.

15.

Added predictive value of omics data: specific issues related to validation illustrated by two case studies.

De Bin R, Herold T, Boulesteix AL.

BMC Med Res Methodol. 2014 Oct 28;14:117. doi: 10.1186/1471-2288-14-117.

16.
17.

Label-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy.

Lacroix C, Caubet C, Gonzalez-de-Peredo A, Breuil B, Bouyssié D, Stella A, Garrigues L, Le Gall C, Raevel A, Massoubre A, Klein J, Decramer S, Sabourdy F, Bandin F, Burlet-Schiltz O, Monsarrat B, Schanstra JP, Bascands JL.

Mol Cell Proteomics. 2014 Dec;13(12):3421-34. doi: 10.1074/mcp.M114.040121. Epub 2014 Sep 9.

18.

Urinary signatures of Renal Cell Carcinoma investigated by peptidomic approaches.

Chinello C, Cazzaniga M, De Sio G, Smith AJ, Gianazza E, Grasso A, Rocco F, Signorini S, Grasso M, Bosari S, Zoppis I, Dakna M, van der Burgt YE, Mauri G, Magni F.

PLoS One. 2014 Sep 9;9(9):e106684. doi: 10.1371/journal.pone.0106684. eCollection 2014.

19.

Immunosignature system for diagnosis of cancer.

Stafford P, Cichacz Z, Woodbury NW, Johnston SA.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3072-80. doi: 10.1073/pnas.1409432111. Epub 2014 Jul 14.

20.

Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease.

Nkuipou-Kenfack E, Duranton F, Gayrard N, Argilés À, Lundin U, Weinberger KM, Dakna M, Delles C, Mullen W, Husi H, Klein J, Koeck T, Zürbig P, Mischak H.

PLoS One. 2014 May 9;9(5):e96955. doi: 10.1371/journal.pone.0096955. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk